ÂÜÀòÂÒÂ×

Kristine Swiderek is Chief Scientific Officer at Mozart Therapeutics. She has more than 25 years of research and leadership experience in the biopharmaceutical industry and a proven track record of discovering and developing a wide variety of protein therapeutics. Prior to Mozart, Dr. Swiderek was Senior VP of Research at Alpine Immune Sciences, where she was instrumental in building a pipeline advancing protein-based immunotherapies for treatment of autoimmune disease and cancer. As Chief Scientific Officer at OncoResponse and Theraclone, she developed and executed research and development strategies. She formed multiple R&D partnerships, advanced several therapeutic candidates into the clinic and was instrumental in the spin-out of OncoResponse. She has also held several positions of increasing responsibility at ZymoGenetics, a publicly-listed company where she advanced over a dozen candidates into clinical development. Dr. Swiderek received her Ph.D. in Protein Biochemistry from the Ruhr-Universität in Bochum, Germany. She completed her postdoctoral studies at City of Hope, Duarte, CA and at Indiana University, Indianapolis, IN. She is the author of over 60 peer-reviewed articles and manuscripts.